key: cord-0908596-8mobf17y
authors: Nile, Shivraj Hariram; Nile, Arti; Jalde, Shivkumar; Kai, Guoyin
title: Recent Advances in Potential Drug Therapies Combating COVID-19 and Related Coronaviruses-A Perspective
date: 2021-06-10
journal: Food Chem Toxicol
DOI: 10.1016/j.fct.2021.112333
sha: afc57c8144c020347a9d93e20fc0ee400e9a861a
doc_id: 908596
cord_uid: 8mobf17y

Coronaviruses (CoVs) are a large family of viruses responsible for the severe pathophysiological effects on human health. The most severe outbreak includes Severe Acute Respiratory Syndrome (SARS-CoV), Middle East Respiratory Syndrome (MERS-CoV) and Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). The COVID-19 poses major challenges to clinical management because no specific FDA-approved therapy yet to be available. Thus, the existing therapies are being used for the treatment of COVID-19, which are under clinical trials and compassionate use, based on in vitro and in silico studies. In this review, we summarize the potential therapies utilizing small molecules, bioactive compounds, nucleoside and nucleotide analogs, peptides, antibodies, natural products, and synthetic compounds targeting the complex molecular signaling network involved in COVID-19. In this review＞230 natural and chemically synthesized drug therapies are described with their recent advances in research and development being done in terms of their chemical, structural and functional properties. This review focuses on possible targets for viral cells, viral proteins, viral replication, and different molecular pathways for the discovery of novel viral- and host-based therapeutic targets against SARS-CoV-2.

The spike proteins present on viral outer surface act as a key that allows the virus to 135 enter the cells of a specific host human body. The binding of viral particle to the surface and related human coronavirus were discussed and presented in Table 1 and 2, with 252 structural details provided as supplementary file (S1). Table 1 and Table 2 , respectively. The structural details of 290 these synthetic and natural protein (enzyme) inhibitors were provided as supplementary 291 file (S1). (Table 1) . Interestingly, most of earlier studies conducted on Table 1 and structural formulas provided as supplementary file (S1). (Table 3 and Supplementary file S1), details about these natural products 336 provided in Table 2 and structural details provided as supplementary file (S1). This 

Recent discovery and 709 development of inhibitors targeting coronaviruses

A review of the antiviral properties of black elder 712 (Sambucus nigra L.) products

Nucleoside analogues for the treatment of 715 coronavirus infections

Convalescent plasma transfusion for the treatment of 719 COVID-19: Systematic review

COVID-19 vaccine: A recent update in p 722 ipeline vaccines, their design and development strategies

Corticosteroids in acute respiratory distress 725 syndrome: a step forward, but more evidence is needed

Clinical evidence does not support 728 corticosteroid treatment for 2019-nCoV lung injury

SARS-CoV 3CLpro inhibitory effects of 732 quinone-methide triterpenes from Tripterygium regelii

COVID-19 768 infection: Origin, transmission, and characteristics of human coronaviruses

Role of corticosteroid in the 771 management of COVID-19: A systemic review and a Clinician's perspective

COVID-19: combining antiviral and anti-inflammatory treatments

Discovery of baicalin and baicalein as novel, natural product 780 inhibitors of SARS-CoV-2 3CL protease in vitro

Identification of a novel inhibitor 783 against middle east respiratory syndrome coronavirus

Structure-activity 787 relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new 788 anti-influenza virus agents

Structural basis 791 of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal 792 plants

RBD= receptor-binding domain

S1/S2 protease cleavage site, S2′= S2′ protease cleavage site, FP= fusion peptide

CD= connector domain, HR2= heptad repeat 2, TM= transmembrane domain, CT= cytoplasmic tail. Arrows denote protease cleavage sites (isolate Wuhan-Hu-1

Binding of spike protein to ACE2, 2: TMPRSS2 helps the virion entry, 3: The virion releases its genomic RNA 4: RNA is translated into proteins by the cell's machinery 5: Proteins forms a replication complex to make more RNA 6: Translation and RNA replication 7: Proteins and RNA are assembled into a new virion in the Golgi and released 8: Packaging of RNA